查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924704

鎂合金血管支架市場：按支架類型、塗層、部署機制、應用和最終用戶分類－2026-2032年全球預測

Mg Alloy Vascular Scaffold Market by Scaffold Type, Coating, Deployment Mechanism, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年鎂合金血管支架市場價值為 2.1255 億美元，預計到 2026 年將成長至 2.4746 億美元，預計到 2032 年將達到 5.8376 億美元，複合年成長率為 15.52%。

關鍵市場統計數據
基準年 2025 2.1255億美元
預計年份：2026年 2.4746億美元
預測年份 2032 5.8376億美元
複合年成長率 (%) 15.52%

簡明扼要、權威地介紹了鎂合金血管支架技術、臨床證據以及血管介入治療領域商業決策者的策略考量。

鎂合金血管支架作為創新選擇，在介入醫學領域再次受到關注。它結合了臨時機械支撐和漸進式生物吸收，從而減少了支架在血管內的長期留置時間。這些支架旨在平衡血管癒合過程中的急性機械性能和可控的溶解過程，最大限度地減少慢性異物反應。隨著支架設計的不斷發展，合金冶金、表面工程和藥物塗層策略的結合，使得支架的分解速率更加可預測，並改善了內皮細胞的反應。

關鍵技術、臨床工作流程、監管協調以及基於價值的採購動態正在共同重塑生物可吸收鎂血管支架的採用路徑。

過去幾年，我們觀察到一系列變革性變化，這些變化正在重新定義人們對血管支架解決方案的預期。合金成分和微觀結構細化的創新，使得材料具有更高的強度重量比和更可預測的腐蝕行為，從而能夠設計出既滿足臨時血管支撐需求又不影響生物相容性的支架。同時，表面改質技術和薄膜藥物塗層的進步，促進了內皮化並抑制了新生內膜增生，縮小了可生物吸收支架和永久性支架之間的性能差距。

2025年醫療設備貿易關稅調整將改變供應鏈、在地化生產和採購趨勢，進而影響定價、市場進入和策略規劃。

預計的貿易政策轉變，包括2025年生效的關稅，將為鎂合金支架價值鏈上的相關人員和策略方面的考量。對醫療設備組件或成品徵收關稅可能會增加依賴跨境供應鏈的製造商的到岸成本，迫使採購團隊重新評估供應商選擇、採購地理和庫存策略。實際上，不斷上漲的進口關稅將迫使製造商實現在地化生產、對本地供應商進行資格認證，或調整材料清單（BOM），以在維持臨床效能的同時降低成本風險。

針對支架類型、臨床應用、終端用戶環境、塗層技術和部署機制等各個方面，提供可操作的見解，以指導產品定位和臨床策略。

了解需求促進因素需要對產品屬性、臨床應用案例、醫療服務環境、塗層策略和部署機制進行詳細細分，因為這些因素都會影響臨床結果和採購優先順序。按支架類型分類，競爭格局包括裸鎂結構、旨在刺激癒合反應的生物活性支架以及旨在釋放抗增殖藥物的藥物釋放型支架。藥物釋放型支架可根據活性成分進一步細分：生物活性成分包括Biolimus、Everolimus和Sirolimus，每種成分都具有不同的藥物動力學和組織相互作用特徵，從而影響血管再阻塞控制和內皮恢復時間。

區域監管差異、臨床基礎設施和供應鏈因素如何影響美洲、歐洲、中東和非洲以及亞太地區的差異化打入市場策略

區域趨勢對監管路徑、臨床醫生採納和供應鏈設計有顯著影響，美洲、歐洲、中東和非洲以及亞太地區的情況各有不同。在美洲，臨床領導者優先考慮長期血管癒合結果的證據和簡化的報銷機制，這迫使器械開發商將試驗終點與支付方的價值框架和醫院採購標準相一致。同時，本地生產能力和監管時間表將影響企業擴大商業性營運規模的速度。

競爭優勢、合作模式、臨床應用路徑，以及主要企業實現差異化並加速鎂合金血管支架解決方案市場接受度的能力。

鎂合金血管支架市場的競爭格局呈現出多元化的特點，既有成熟的心血管器械製造商，也有專注於生物可吸收材料的專業研發公司，以及從合金生產到成品全產業鏈的垂直整合型企業。主要企業往往重視開發平臺，整合冶金、表面工程和藥物製劑等領域的專業知識，以實現差異化的分解特性和更佳的安全性。材料科學團隊、塗層專家和臨床研究機構之間的策略聯盟加速了從研究到臨床應用的轉化。

一項切實可行的跨職能策略，結合材料創新、臨床證據項目、供應鏈韌性和市場進入途徑，以加速永續應用。

產業領導者應優先考慮一種協作策略，該策略應平衡材料科學的投資與實際的臨床和商業性努力。首先，他們將資源投入到迭代合金最佳化和表面工程中，以減少分解曲線的變異性並提高生物相容性。這些技術投資，結合以機制終點為重點的可靠的臨床前和早期臨床試驗，將建構更強力的證據基礎。同時，企業應設計臨床醫生參與計劃，透過研討會、影像引導治療通訊協定和指導等方式規範植入技術，從而最大限度地減少早期實施階段的技術差異。

我們採用透明的混合方法，結合臨床醫師訪談、材料科學文獻、監管溝通和供應鏈分析，提供實證策略指導。

本執行摘要的調查方法融合了原始定性資料和有針對性的二手證據綜合分析，旨在建立一個臨床支持且平衡的觀點。原始數據包括對介入性心臟病專家、介入神經放射學、血管外科醫生、採購人員和監管顧問的結構化訪談，以了解他們對器械性能的真實認知、手術推廣障礙以及報銷方面的考慮。這些訪談旨在揭示器械的運作機制、臨床醫生的工作流程偏好以及影響醫院採購決策的因素。

策略整合強調技術檢驗、臨床醫生培訓、法規遵循和永續商業化是實現長期臨床和商業性成功的關鍵。

鎂合金血管支架在介入治療中佔有重要的地位，它能夠提供暫時的機械支撐，並透過可控吸收來實現長期的異物負荷減輕。合金技術的進步、塗層技術的應用、最佳手術操作規範以及不斷完善的監管路徑之間的相互作用，正在創造一個充滿活力的環境，在這個環境中，那些能夠整合卓越技術、嚴謹的臨床證據和切實可行的商業化策略的企業將取得成功。臨床醫生培訓、影像引導下的留置技術以及完善的上市後資料收集，將在證明支架的持續安全性和功能恢復方面發揮關鍵作用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 鎂合金血管支架市場（依支架類型分類）

  • 熊
  • 生物活性
  • 藥物釋放型型
    • Biolimus洗脫型
    • Everolimus洗脫
    • Sirolimus洗脫

9. 鎂合金血管支架市場（依塗層分類）

  • 未塗層
  • 聚合物塗層
    • 可生物分解聚合物
    • 耐用聚合物

第10章：鎂合金血管支架市場發展機制分析

  • 氣球膨脹類型
  • 自膨脹

第11章 鎂合金血管支架市場（按應用領域分類）

  • 冠狀動脈
    • 急性心肌梗塞
    • 穩定性心絞痛
  • 神經血管
    • 動脈瘤
    • 缺血性中風
  • 外圍
    • 下肢動脈
    • 腎動脈

第12章 鎂合金血管支架市場（依最終用戶分類）

  • 門診手術中心
  • 心臟導管檢查室
  • 醫院

13. 鎂合金血管支架市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 鎂合金血管支架市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國鎂合金血管支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國鎂合金血管支架市場

第17章 中國鎂合金血管支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AmsinoMed Medical Co., Ltd
  • Arterial Remodeling Technologies, Inc.
  • Biotronik SE & Co. KG
  • Elixir Medical Corporation
  • FY MedTech
  • Magnesium Elektron Ltd.
  • Q3 Medical Devices
  • QualiMed, Inc.
  • Shanghai Pulin Medical Technology Co., Ltd.
  • SINOMED Co., Ltd.
Product Code: MRR-7A380DA7C43B

The Mg Alloy Vascular Scaffold Market was valued at USD 212.55 million in 2025 and is projected to grow to USD 247.46 million in 2026, with a CAGR of 15.52%, reaching USD 583.76 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 212.55 million
Estimated Year [2026] USD 247.46 million
Forecast Year [2032] USD 583.76 million
CAGR (%) 15.52%

Concise authoritative framing of magnesium alloy vascular scaffold technologies, clinical rationale, and strategic considerations for executive decision-makers in interventional vascular care

Magnesium alloy vascular scaffolds are re-emerging as a transformative option in interventional medicine, blending temporary mechanical support with progressive bioresorption to reduce long-term device presence in the vasculature. These scaffolds seek to deliver a balance between acute mechanical performance during vessel healing and a controlled dissolution profile that minimizes chronic foreign body reaction. As device design evolves, the convergence of alloy metallurgy, surface engineering, and drug coating strategies is enabling more predictable degradation kinetics and improved endothelial responses.

This executive summary synthesizes current technological advancements, clinical adoption dynamics, regulatory trajectories, and commercial forces shaping the landscape. It is informed by recent peer-reviewed evidence, regulatory communications, and observed shifts in hospital procurement preferences. The intent is to provide senior leaders with a clear narrative of how magnesium alloy scaffold technologies are positioned relative to permanent metallic stents and polymeric bioresorbable scaffolds, and to highlight strategic inflection points for portfolio development, clinical trial design, and market access planning.

Throughout the document, discussion emphasizes mechanism-driven performance attributes, clinician adoption drivers, and the interplay between reimbursement environments and hospital infrastructure. The goal is to equip decision-makers with actionable context that informs R&D prioritization, clinical engagement strategies, and partnership selection in a rapidly evolving interventional device ecosystem.

Critical technology, clinical workflow, regulatory adjustments, and value-based purchasing dynamics that are jointly reshaping adoption pathways for bioresorbable magnesium vascular scaffolds

The past several years have witnessed a sequence of transformative shifts that are recalibrating expectations for vascular scaffolding solutions. Innovations in alloy composition and microstructure refinement have yielded materials with improved strength-to-weight ratios and more predictable corrosion behavior, enabling designs that better match transient vessel support requirements without compromising biocompatibility. Parallel advances in surface modification techniques and thin-film drug coatings have enhanced endothelialization while mitigating neointimal proliferation, narrowing the performance gap between bioresorbable and permanent devices.

Clinical methodology has evolved concurrently, with interventionalists adopting imaging-guided implantation workflows and more selective lesion preparation strategies that optimize scaffold apposition and reduce acute mechanical complications. Health systems are responding by investing in cath lab imaging capabilities and training that support adoption of next-generation scaffolds. Regulatory frameworks in major markets are also adapting, increasingly accommodating iterative device improvements through targeted clinical pathways and post-market surveillance expectations that allow companies to refine materials and coatings while maintaining patient safety oversight.

Commercial dynamics are shifting as hospitals and payors evaluate total episode-of-care value rather than the device price alone. This broader perspective creates opportunities for stakeholders who can demonstrate reductions in downstream complication rates, shorter recovery times, or meaningful improvements in patient-reported outcomes. The net effect of these technological, clinical, regulatory, and commercial forces is a landscape characterized by accelerated innovation cycles, closer collaboration between device developers and clinician leaders, and an expectation that safety and long-term vascular healing will determine sustainable adoption.

How 2025 tariff shifts on medical device trade create supply chain, manufacturing localization, and procurement dynamics that materially affect pricing, access, and strategic planning

Anticipated trade policy shifts, including tariff measures enacted in 2025, introduce a layered set of operational and strategic considerations for stakeholders in the magnesium alloy scaffold value chain. Tariffs on medical device components or finished devices can increase landed costs for manufacturers that rely on cross-border supply chains, prompting procurement teams to reassess supplier selection, sourcing geographies, and inventory strategies. In practice, rising import duties exert pressure on manufacturers to localize manufacturing, qualify regional suppliers, or reconfigure bill-of-materials to mitigate cost exposure while preserving clinical performance.

Clinicians and hospital administrators will experience indirect effects through procurement cycles and capital planning. Hospitals may accelerate conversations with suppliers about total cost of care and value-based contracting to offset potential price adjustments. Device developers with vertically integrated manufacturing or regional production capacity will have a relative advantage as they can insulate pricing and delivery timelines from tariff volatility. Additionally, tighter margins can influence how companies allocate investment across clinical evidence generation and post-market surveillance, sometimes favoring partnerships that share trial or registry costs.

From a regulatory and reimbursement standpoint, tariffs can alter the economic calculus for market entry strategies, altering timelines for establishing local distributor networks versus direct-market operations. It is essential for industry leaders to conduct scenario planning that models supply chain rerouting, contract renegotiation, and capital investment in regional production to maintain competitiveness and ensure uninterrupted access to innovative scaffold technologies for patients.

Actionable insights across scaffold type, clinical applications, end-user settings, coating technologies, and deployment mechanisms to guide product positioning and clinical strategy

Understanding demand drivers requires granular segmentation across product attributes, clinical use-cases, provider settings, coating strategies, and deployment mechanisms, each of which shapes clinical outcomes and procurement priorities. By scaffold type, the competitive field includes bare magnesium constructs, bioactive variants engineered to stimulate healing responses, and drug-eluting scaffolds designed to deliver antiproliferative agents; the drug-eluting category further differentiates by the active compound, where biolimus, everolimus, and sirolimus each carry distinctive pharmacokinetic and tissue interaction profiles that influence restenosis control and endothelial recovery timelines.

Application-specific insights reveal divergent clinical needs across coronary, neurovascular, and peripheral territories. Coronary use splits along acute presentation versus stable disease, where acute myocardial infarction cases demand immediate mechanical reliability and predictable resorption, while stable angina interventions prioritize long-term vessel patency and patient quality of life. Neurovascular applications address aneurysm repair and ischemic stroke adjunctive support, requiring scaffolds that balance radial support with minimal inflammatory footprint in delicate cerebral vessels. Peripheral indications, covering lower limb artery and renal artery treatments, impose unique mechanical flexibility and corrosion-resistance requirements because of differing hemodynamic stresses and vessel sizes.

End-user settings shape adoption patterns and service-level expectations; ambulatory surgical centers, cardiac catheterization labs, and hospitals each have distinct imaging capabilities, clinician expertise levels, and purchasing frameworks that affect which scaffold profiles are preferred. Coating strategy plays a pivotal role in matching device behavior to clinical objectives, with non-coated scaffolds offering simplicity and faster resorption and polymer-coated options-biodegradable or durable polymers-enabling controlled drug release and modified surface interactions. The deployment mechanism, whether balloon expandable or self-expanding, further determines procedural workflow and lesion selection, affecting clinician training needs and inventory management. Integrating these segmentation axes into product development and commercial plans enables more precise targeting of clinical evidence and reimbursement positioning.

How regional regulatory variance, clinical infrastructure, and supply chain considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated market entry strategies

Regional dynamics exert a pronounced influence on regulatory pathways, clinician adoption, and supply chain design, with distinct considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical leaders emphasize evidence demonstrating long-term vascular healing outcomes and streamlined reimbursement mechanisms, prompting device developers to align trial endpoints with payer value frameworks and hospital procurement criteria. Meanwhile, local manufacturing capabilities and regulatory timelines influence how quickly firms can scale commercial operations.

Across Europe, the Middle East & Africa, diversity in regulatory regimes and hospital infrastructure drives a need for adaptable market access approaches. Some markets prioritize centralized clinical data and robust post-market registries, while others prioritize rapid adoption if clinical benefits align with existing practice. In Asia-Pacific, rapid investment in interventional cardiology infrastructure, coupled with large patient volumes and competitive domestic manufacturers, creates both opportunity and pressure; device designers must consider cost-sensitive procurement while also addressing clinician demands for advanced imaging and implantation tools.

These regional contrasts demand tailored commercialization blueprints: a unified global value proposition must be complemented by region-specific evidence generation, supply chain localization strategies, and clinical affairs programs that resonate with local key opinion leaders and regulatory expectations. Strategic partnerships with regional distributors, clinical centers, and manufacturing partners can accelerate market preparedness and mitigate tariff, logistic, or regulatory hurdles.

Competitive dynamics, collaboration models, clinical adoption pathways, and capabilities that distinguish leading companies and accelerate acceptance of magnesium alloy vascular scaffold solutions

The competitive landscape for magnesium alloy vascular scaffolds is characterized by a mix of established cardiovascular device manufacturers, specialized developers focused on bioresorbable materials, and vertically integrated firms that control alloy production through to finished devices. Companies leading technological advances often emphasize integrated R&D pipelines that combine metallurgy, surface engineering, and drug formulation expertise to deliver differentiated degradation profiles and improved safety signals. Strategic alliances between material science groups, coating specialists, and clinical research organizations accelerate translation from bench to bedside.

Clinical adoption often follows a pattern where early clinical adopters at high-volume centers validate procedural workflows and generate peer-reviewed evidence. Manufacturers that invest in targeted investigator-initiated studies and multi-center registries gain credibility with clinicians and payors by demonstrating procedural reproducibility and safety across diverse lesion types. At the same time, firms that offer comprehensive procedural support-training, imaging protocols, and proctoring-reduce clinician learning curves and enhance the probability of favorable clinical outcomes.

From a commercial perspective, companies that demonstrate supply chain resilience, local manufacturing options, and flexible pricing arrangements typically secure preferred access within hospital procurement systems. Given the complexity of bringing bioresorbable scaffold technologies to market, many firms pursue partnerships or licensing agreements to combine clinical evidence generation capacity with established distribution networks and clinician relationships.

Practical cross-functional strategies combining material innovation, clinical evidence programs, supply chain resilience, and market access pathways to accelerate sustainable adoption

Industry leaders should prioritize a coordinated strategy that balances material science investment with pragmatic clinical and commercial initiatives. First, allocating resources to iterative alloy optimization and surface engineering will reduce variability in degradation profiles and improve biocompatibility; coupling these technical investments with robust preclinical and early clinical studies focused on mechanism-based endpoints will create a stronger evidentiary foundation. Simultaneously, companies should design clinician engagement programs that standardize implantation technique through hands-on workshops, image-guided procedural protocols, and proctoring to minimize technical variability during early adoption.

Second, supply chain resilience must be elevated as a strategic objective. Scenario planning should assess the benefits of regional manufacturing or dual-sourcing strategies to insulate operations from tariff shifts and logistic disruptions. Negotiating value-based contracts and risk-sharing arrangements with health systems can align incentives around long-term patient outcomes, and these arrangements should be supported by real-world evidence generation through registries and post-market studies. Finally, pursue targeted partnerships for market entry that combine local regulatory expertise with distribution capability, enabling flexible commercialization models that respond to regional payer landscapes and clinician preferences.

Implementing this multi-dimensional approach will require cross-functional coordination across R&D, clinical affairs, regulatory, manufacturing, and commercial teams, but it also offers a practical pathway to accelerate adoption while managing cost and access risks inherent in complex device categories.

Transparent mixed-methods approach combining clinician interviews, materials science literature, regulatory communications, and supply chain analysis to inform evidence-based strategic guidance

The research methodology underpinning this executive summary blends primary qualitative inputs with targeted secondary evidence synthesis to generate a balanced, clinically anchored perspective. Primary inputs include structured interviews with interventional cardiologists, neurointerventional specialists, vascular surgeons, procurement leaders, and regulatory advisers to capture real-world device performance perceptions, procedural adoption barriers, and reimbursement considerations. These interviews were designed to surface mechanistic insights, clinician workflow preferences, and criteria that influence hospital purchasing decisions.

Secondary evidence was assembled from peer-reviewed clinical studies, regulatory agency communications, device labeling information, materials science literature on magnesium alloys and coatings, and publicly available clinical registry outcomes. Where possible, triangulation was applied to corroborate claims across data sources and to contextualize device performance relative to established clinical endpoints. In addition, supply chain analyses incorporated trade and logistics publications and public filings to evaluate manufacturing footprints and potential exposure to tariff and import risks.

The methodological approach emphasizes transparency about data provenance, the limitations of available evidence, and the need for ongoing post-market surveillance to validate early clinical findings. Readers should interpret recommendations as strategic guidance grounded in current clinical practice and material science developments rather than definitive predictions about future market trajectories.

Strategic synthesis emphasizing technical validation, clinician training, regulatory alignment, and resilient commercialization as keys to long-term clinical and commercial success

Magnesium alloy vascular scaffolds occupy an important niche within interventional therapy, offering the promise of temporary mechanical support followed by controlled resorption that reduces long-term foreign body burden. The interplay of alloy advancements, coating technologies, procedural best practices, and evolving regulatory pathways creates a dynamic environment where successful players will be those who integrate technical excellence with rigorous clinical evidence and pragmatic commercialization strategies. Clinician training, imaging-supported implantation techniques, and robust post-market data capture will be central to demonstrating durable safety and functional recovery.

Organizational readiness to respond to trade policy shifts, supply chain interruptions, and regional regulatory nuance will also determine how quickly innovations translate into routine clinical practice. Companies that align R&D priorities with clear clinical endpoints, invest in real-world evidence generation, and develop flexible manufacturing and distribution strategies will be better positioned to navigate complexity. Ultimately, patient-centric outcomes-reduced complications, restored vessel function, and improved quality of life-should remain the north star for product development and commercialization choices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mg Alloy Vascular Scaffold Market, by Scaffold Type

  • 8.1. Bare
  • 8.2. Bioactive
  • 8.3. Drug Eluting
    • 8.3.1. Biolimus Eluting
    • 8.3.2. Everolimus Eluting
    • 8.3.3. Sirolimus Eluting

9. Mg Alloy Vascular Scaffold Market, by Coating

  • 9.1. Non Coated
  • 9.2. Polymer Coated
    • 9.2.1. Biodegradable Polymer
    • 9.2.2. Durable Polymer

10. Mg Alloy Vascular Scaffold Market, by Deployment Mechanism

  • 10.1. Balloon Expandable
  • 10.2. Self Expanding

11. Mg Alloy Vascular Scaffold Market, by Application

  • 11.1. Coronary
    • 11.1.1. Acute Myocardial Infarction
    • 11.1.2. Stable Angina
  • 11.2. Neurovascular
    • 11.2.1. Aneurysm
    • 11.2.2. Ischemic Stroke
  • 11.3. Peripheral
    • 11.3.1. Lower Limb Artery
    • 11.3.2. Renal Artery

12. Mg Alloy Vascular Scaffold Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Catheterization Labs
  • 12.3. Hospitals

13. Mg Alloy Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Mg Alloy Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Mg Alloy Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Mg Alloy Vascular Scaffold Market

17. China Mg Alloy Vascular Scaffold Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AmsinoMed Medical Co., Ltd
  • 18.6. Arterial Remodeling Technologies, Inc.
  • 18.7. Biotronik SE & Co. KG
  • 18.8. Elixir Medical Corporation
  • 18.9. FY MedTech
  • 18.10. Magnesium Elektron Ltd.
  • 18.11. Q3 Medical Devices
  • 18.12. QualiMed, Inc.
  • 18.13. Shanghai Pulin Medical Technology Co., Ltd.
  • 18.14. SINOMED Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 189. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 222. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 223. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 224. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 233. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 234. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 235. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)